Memo Therapeutics AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Safety, Tolerability and Efficacy of AntiBKV As Treatment of BKV Infection in Kidney Transplant Recipients
Phase 2
Active, not recruiting
- Conditions
- BK Viremia; BKV DNAemia
- Interventions
- Biological: Anti-BK polyomavirus (AntiBKV)
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Memo Therapeutics AG
- Target Recruit Count
- 180
- Registration Number
- NCT05769582
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.
Phase 1
Completed
- Conditions
- BK Virus Nephropathy
- Interventions
- Biological: PlaceboBiological: AntiBKV
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Memo Therapeutics AG
- Target Recruit Count
- 40
- Registration Number
- NCT05358106
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Memo Therapeutics AG
- Target Recruit Count
- 32
- Registration Number
- NCT05351437
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia